Blue Jet Healthcare Expansion in Andhra Pradesh : Pharma Company Secures Land in APIIC’s Rambilli Cluster for Long-Term Capacity Growth
Blue Jet Healthcare Expansion in Andhra Pradesh : – Blue Jet Healthcare Ltd. a specialty pharmaceutical company has received approval from its Board of Directors to acquire 102.48 acres of industrial land in Andhra Pradesh’s Rambilli Industrial Park for establishing a new manufacturing facility. The land allotment by the Andhra Pradesh Industrial Infrastructure Corporation (APIIC) marks a strategic step in the company’s long-term capacity expansion to meet growing demand across key therapeutic segments.
Key Details of the Expansion Plan
1. Land Acquisition & Investment
✔ Location: Rambilli Industrial Park, Phase II (Anakapalli District, AP)
✔ Land Area: 102.48 acres (allotted by APIIC)
✔ Purpose: New API & formulation manufacturing facility
✔ Therapeutic Focus: Niche & high-value pharmaceuticals
2. Strategic Rationale
✅ Capacity Expansion: Supports long-term demand growth in domestic & export markets
✅ Operational Synergies: Proximity to Visakhapatnam Port for global shipments
✅ Andhra Pradesh’s Pharma Push: Aligns with state’s Bulk Drug Policy & PLI incentives
3. Next Steps
🔹 Detailed project report (DPR) finalization (Q3 2025)
🔹 Regulatory approvals & construction timeline (2026-27)
🔹 Potential investment scale: Likely ₹800–1,000 crore+ (as per industry benchmarks)
Why Rambilli, Andhra Pradesh?
✅ APIIC’s Pharma-Focused Infrastructure
- Dedicated bulk drug parks with common effluent treatment plants (CETPs)
- Plug-and-play utilities (power, water, logistics)
✅ Proximity to Key Pharma Hubs
- Visakhapatnam Port (45 km) for API exports
- Hyderabad-Bengaluru industrial corridor connectivity
✅ Policy Support
- Andhra’s Bulk Drug Policy (subsidies for API manufacturing)
- PLI Scheme for Pharmaceuticals eligibility
Industry & Market Implications
1. Strengthening India’s API Ecosystem
- Reduces import reliance for critical drug ingredients
- Complements national drug security goals
2. Job Creation & Regional Growth
- Expected 500+ direct jobs in Phase 1
- Boost to Anakapalli’s industrial development
3. Export Potential
- USFDA/EMA-compliant facility likely to target regulated markets
Leadership Perspective
Blue Jet Healthcare Spokesperson:
“This expansion aligns with our vision to scale high-value therapeutic production. Andhra Pradesh’s infrastructure and policy ecosystem make Rambilli an ideal choice.”
APIIC Official:
“Rambilli is emerging as a pharma & bulk drug hub. Blue Jet’s investment validates our industrial cluster strategy.”
What’s Next?
🔹 2025: Finalizing capex plans & technology partners
🔹 2026: Groundbreaking & construction start
🔹 2028: Potential commercial production
Conclusion:
Blue Jet’s 102-acre Andhra Pradesh facility signals a major leap in India’s API & specialty pharma capabilities. With strategic port access and policy tailwinds, this project could position the company as a key player in the global pharmaceutical supply chain.
Key Monitorables:
- Capex details & funding mix
- Regulatory clearances timeline
- Partnerships with CDMOs/global pharma
